An Attractive IP Portfolio Centered on Ear Diseases
Our first small molecule drug discovery program is for treating sensorineural hearing loss. The goal of the program is to optimize small molecules in proof of concept studies as preclinical candidates for treatment of hearing loss.
We are currently in the process of expanding and developing our IP portfolio to include ear drug delivery systems as well as discovering and developing additional small molecule drugs for inner and middle ear diseases.
If you are developing new treatments or delivery systems for inner and middle ear diseases, please contact us to discuss potential partnerships aimed at bringing new and better treatments to patients.